Introduction
Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy with a prevalence of up to 1 in 2500 (Skre, 1974; Martyn and Hughes, 1997) . In 450% of all cases, the genetic defect underlying CMT is an intrachromosomal duplication spanning 1.4 Mb on human chromosome 17p12, the locus defining CMT subtype 1A (Lupski et al., 1991; Raeymaekers et al., 1991) . The gene encoding the peripheral myelin protein of 22 kDa (PMP22) is located in the duplicated region and was identified as the responsible disease gene (Matsunami et al., 1992; Patel et al., 1992; Timmerman et al., 1992; Valentijn et al., 1992) . Patients with CMT subtype 1A display slowly progressive weakness and atrophy predominantly in distal muscles and absent reflexes with a typical onset at adolescence (Thomas et al., 1997; Krajewski et al., 2000; Shy et al., 2005b; Parman, 2007; Pareyson et al., 2009) . Patients also show sensory loss and foot deformities. The ultimate clinical phenotype of CMT subtype 1A is determined by the amount of secondary axonal loss (Berciano et al., 2000) . Despite its monogenetic cause, patients with CMT subtype 1A display a marked interindividual variability of disease severity, even in the same family and among monozygotic twins (Kaku et al., 1993; Garcia et al., 1995) . The reason for this variability is largely unknown and epigenetic factors have been discussed (Steiner et al., 2008; Pareyson et al., 2009) .
To date, only physical and electrophysiological examinations are available to determine disease severity in patients with CMT subtype 1A. The CMT neuropathy score is a validated nine-item composite scale taking into account sensory and motor symptoms (Shy et al., 2005a) . The CMT neuropathy score is currently being applied as the primary outcome measure for CMT subtype 1A trials (Reilly et al., 2010) . Neither trials of exercise and orthosis, nor pharmacological approaches with ganglioside, creatine and very recently, oral administration of ascorbic acid showed beneficial effects in patients with CMT subtype 1A (Young et al., 2008; Burns et al., 2009; Micallef et al., 2009; Verhamme et al., 2009; Pareyson et al., 2011) . For ascorbic acid, it was suggested that a small effect may have been missed because of unexpectedly slow progression of the disease by only 0.5 CMT neuropathy score points over 2 years (0.25 points per year) (Pareyson et al., 2011) although the progression of the CMT neuropathy score was initially reported to increase $0.68 points per year (Shy et al., 2005a) . Thus, limitations of the CMT neuropathy score may underlie the negative therapy outcomes in recent clinical trials (de Visser and Verhamme, 2011; Pareyson et al., 2011) .
Surrogate markers of disease severity could add powerful tools to monitor therapeutic effects in clinical trials (Reilly et al., 2010; Pareyson et al., 2011) . Furthermore, at present, young patients with CMT subtype 1A cannot be adequately counselled on their individual disease course. Prognostic markers of disease severity would provide patients with important information regarding future life, and also may influence the decision to start a therapy at early time points.
Transgenic rats (CMT rats) that harbour additional copies of Pmp22 closely phenocopy the pathology and the clinical symptoms of patients with CMT subtype 1A (Sereda et al., 1996 (Sereda et al., , 2003 . Importantly, CMT rats kept on an outbred genetic background also develop a highly variable severity of disease, similar to patients with CMT subtype 1A (Sereda et al., 2003) . PMP22 expression measured in skin biopsies from patients with CMT subtype 1A did not correlate with disease severity ) consistent with our data from CMT rats (Meyer zu Hö rste et al., 2007) . Thus, the need for biomarkers is left open. We therefore addressed the question whether the expression of other genes can be utilized to detect disease severity in CMT subtype 1A. We first examined transcriptional biomarkers for the assessment and prognosis of disease severity in the CMT rat model. We then validated these biomarkers from the CMT rat in skin biopsies of human patients with CMT subtype 1A.
Materials and methods

Transgenic rats
The generation of Pmp22 transgenic CMT rats has been described previously (Sereda et al., 1996) . Routine genotyping was performed by polymerase chain reaction, using genomic DNA from tail biopsies and mouse transgene-specific primers under standard conditions as described (Sereda et al., 1996) . All experiments were performed according to the German regulations of Lower Saxony for animal experimentation. Only male rats were used.
Phenotyping
All phenotype analyses were performed by the same investigator who was blinded towards genotype. Motor performance was assessed in standardized grip strength tests for fore-limbs as previously described (Meyer et al., 1979) . With their fore-limbs, the animals gripped a horizontal T-bar (width 14 cm, diameter 3.2 mm) connected to a gauge while the investigator pulled their tail proximally from the bar with increasing force. The maximum force (measured in Newton) exerted onto the T-bar before the animals lost grip was recorded.
Hot plate test
This nociceptive test was applied according to a published protocol (Bannon and Malmberg, 2007) . Rats were allowed to habituate for 10 min before testing. Pain reflexes in response to a thermal stimulus were measured using a Hot Plate Analgesia Meter (Columbus). The surface of the hot plate was heated to a constant temperature of 55 C, as measured by a built-in digital thermometer with an accuracy of 0.1 C and verified by a surface thermometer. Rats were placed on the hot plate (25.4Â 25.4 cm), which is surrounded by a clear acrylic cage (30 cm high, open top), and the Start/Stop button on the timer was activated. The latency to respond with either a hindpaw lick, hindpaw flick or jump (which ever comes first) was measured to the nearest 0.1 s by deactivating the timer when the response was observed. The rat was immediately removed from the hot plate and returned to its home cage. If a rat did not respond within 60 s, the test was terminated and the rat removed from the hot plate. Animals were tested one at a time and were not habituated to the apparatus prior to testing. Each animal was tested only once.
Electrophysiological recordings
Nerve conduction velocities and compound muscle action potentials were determined at 9 weeks of age as described previously (Meyer zu Hö rste et al., 2007) . Briefly, animals were anaesthetized using an intraperitoneal injection of ketamin (100 mg/kg) and xylazin (5 mg/kg), while constant body temperature was maintained using a heating plate connected to a rectal temperature sensor (CMA). Tail nerve conduction velocity proved to be more reproducible than recordings from the sciatic nerve, which had to be exposed surgically. Stimulation was performed with increasing voltage until supramaximal stimulation was achieved. Maximum compound muscle action potential voltage was recorded from tail muscle with fine subcutaneous needle electrodes using a Jaeger-Toennies Neuroscreen instrument.
Compound muscle action potential amplitudes were calculated peak to peak. Nerve conduction velocity was calculated from distance and motor latency differences between proximal and distal stimulations.
Tissue preparation
At post-natal Day 5, a skin biopsy from the tail was collected from each animal after short CO 2 narcosis, for genotype determination by polymerase chain reaction. Sciatic nerve and skin biopsies (from operation wound) were taken at post-natal Day 7, before onset of disease, and collected in liquid nitrogen and stored at À 80 C. After 9 weeks of age (Day 63), all rats were sacrificed by CO 2 narcosis. Again, one skin biopsy from the tail was dissected from each animal, collected on liquid nitrogen and stored at À80 C. At both time points, Days 7 and 63, the surrounding connective and fatty tissue of the sciatic nerve, found in the epineurium, was carefully removed with a razor blade. Then the animal was perfused with Hanks' buffered salt solution, followed by a modified fixation with 2.5% glutaraldehyde and 4% paraformaldehyde in phosphate buffer (Karlsson and Schultz, 1965; Sereda et al., 1996) .
Histology of peripheral nerve
After perfusion, one tibial nerve was dissected and embedded in epoxy resin (Luft, 1961) . Semi-thin sections (0.5 mm) of tibial nerves were cut at level with the medial ankle. Sections were stained with methylene blue-Azur II and photographed using a standard video frame grabber (ProgRes C14, Jenoptic) installed on a Zeiss Axiophot microscope. Overlapping photographs of the entire nerves were taken and merged using PanoToolsAssembler software. After blinding, the entire number of axons per tibial nerve was counted manually by the same investigator using the CellCounter plugin of ImageJ (v1.36, NIH) . Each individual axon was manually marked and automatically counted. Physiologically unmyelinated axons (diameter 51 mm) and Remak-bundle fibres were not included.
RNA isolation, labelling and microarray hybridization
RNA preparation was performed according to the manufacturer instructions without adding any carrier (RNeasy Õ Lipid tissue Mini Kit, Qiagen). RNA quality and quantity of control samples was checked by analysing aliquots on the Agilent 2100 Bioanalyser using the RNA 6000 Pico LabChip kit (Agilent Technologies). Total RNAs of all sample groups were stored at À80 C and were processed in parallel.
Immediately before amplification, RNA was precipitated by adding Na-acetate (pH 5.2, 0.3 M, final concentration), 2 ml of PelletPaint (Calbiochem; Novabiochem) and ethanol. Total RNA was resuspended with pretested T7-tagged dT21V oligonucleotides as previously described (Rossner et al., 2006) . One-round T7-RNA polymerasemediated linear amplification and biotin labelling was performed according to specifications given by the manufacturer (Affymetrix). Biotin-labelled amplified RNA size distribution and quantity was analysed with the Agilent 2100 Bioanalyser using the RNA 6000 Nano LabChip kit (Agilent Technologies). Hybridization, washing, staining and scanning were performed under standard conditions as described by the manufacturer (Affymetrix). Rat Gene 1.0 ST tiling arrays were used that cover more than 27 000 transcripts.
Microarray data analysis
Data analysis was performed using the integrated software packages Genomics Suite (Partek Inc.) and R-scripts (www.bioconductor.org). Raw data were normalized using the RMA algorithm and differentially expressed genes were identified with ANOVA according to the workflow suggested by the manufacturer and with cut-offs at 41.3-fold change and P-values 50.001 (Partek Inc.). The identification of coordinated changes in a priori defined sets of functionally grouped genes was performed using the Gene Set Enrichment Analysis approach (Mootha et al., 2003) . The gene set enrichment analysis software package was downloaded and locally implemented (www.broadinstitute.org/gsea) and used with default parameters (permutations set to 1000) and all available gene sets available in the molecular signature database (MSigDB v3.0).
Semi-quantitative real time-polymerase chain reaction
Real time-polymerase chain reaction reactions (SYBR Õ Green polymerase chain reaction assay for rat tissue, TaqMan Õ polymerase chain reaction assay for human tissue) were carried out using the ABI Prism 7500 Sequence Detection System (Applied Biosystems). A real time-polymerase chain reaction master mix was prepared to a final reaction volume of 10 ml. The real time-polymerase chain reaction followed the standard two-step protocol and quantitation of polymerase chain reaction product was performed using the comparative &nbsp;ÁÁCt method as recommended by the manufacturer. All real time-polymerase chain reactions were carried out in triplicate and averaged. All TaqMan Õ primers and probe sets were designed using the primer express software V. 
Skin biopsies
The skin biopsy of the patient was taken from the proximal, medial part of the index finger of the non-dominant hand at the end of all examinations to avoid any influences of other test results. The surgery was performed under sterile conditions of the operation field as well as under local anaesthesia with 1% lidocaine. The sterile disposables of 3 mm, biopsy punch by Stiefel was used and sterile steri-strips (3M) were applied. The skin biopsy was separated into two equal parts, one placed in 4% paraformaldehyde in 1Â phosphate-buffered saline, the other in RNAlater Õ (Ambion). To avoid any damage, the biopsies were carried in a box with ice to the laboratory and stored at À 20 C (RNAlater Õ ) and 4 C (paraformaldehyde) for further examination.
Statistical analysis
All values are expressed as mean AE SEM unless indicated otherwise. All data were tested on Gaussian distribution (Kolmogorow-SmirnowLilliefors test) and where applicable, used parametric (Student's t-test) or non-parametric (Willcoxon-Mann-Whitney U-test) testing. Correlation analyses were performed using the Spearman's rank correlation test. Statistica 6.0 (StatSoft) was used for statistical analyses in rats. Statistical analysis of human real time-polymerase chain reaction expression analysis with regard to collected clinical data was performed by U.H. and W.K. and is extensively described in a statistical report in Supplementary material. Analysis was performed via step-wise linear regression with forward and backward stepping procedures. The variables in the multiple linear model for CMT neuropathy score were used to determine multiplicity adjusted P-values and were presented in addition to the usual P-values to assess the statistical association of markers and demographic variables with CMT neuropathy score. Leverage plots were used to visualize the association of the individual data of each variable with the target variable in the multiple linear models.
Results
Charcot-Marie-Tooth rats display clinical variability
In 50 randomly chosen CMT rats, skin and sciatic nerve samples were collected both at Day 7, i.e. before onset of clinical phenotype, and again at 9 weeks of age (Day 63) when they display clinical impairments (Fig. 1A) .
The progression of the clinical phenotype was tracked by grip strength measurements at 3, 5, 7 and 9 weeks of age, demonstrating significant differences between wild-type rats (n = 6) and CMT rats (n = 50) from 5 weeks onwards (P 5 0.05; Fig. 1B ). The grip strength at 9 weeks of age, when rats were sacrificed, was used for the identification of mildly and severely affected CMT rats (Fig. 1B) . In order to strengthen the primary selection criterion, rats with most extreme values in grip strength were also subjected to electrophysiological (Fig. 1C and D) , nociceptive (hot plate) ( Fig. 1G and H) and histological ( Fig. 1E and F) analysis.
Electrophysiological recordings (representative traces in Fig. 1C ) revealed a reduction in compound muscle action potential amplitudes in CMT rats compared with wild-type rats (4.91 AE 0.59 mV; n = 9). Importantly, severely affected CMT rats (1.32 AE 0.16 mV; n = 10) showed a further decrease in compound muscle action potentials compared with mildly affected rats (3.25 AE 0.37 mV; n = 7) (Fig. 1D ). In contrast, nerve conduction velocities were significantly lower in CMT rats compared with wild-type rats whereas no difference was observed between mildly and severely affected CMT rats (data not shown). This suggests that the extent of axonal loss rather than demyelination determines individual differences of disease severity (Meyer zu Hö rste et al., 2007) .
Additionally, we analysed the sensory phenotype of CMT rats with the nociceptive hot plate test where rats respond to heat pain by hindpaw licking (Fig. 1G ). Pain response latencies were unaltered between wild-type animals (28.98 AE 2.95 s) and mildly affected CMT rats (33.95 AE 2.06 s) but we observed a significant sensory impairment in severely affected CMT rats (46.63 AE 2.62 s, P 5 0.005 compared with wild-type and mildly affected CMT rats). That nociceptive impairments correlate with disease severity, whereas motor nerve conduction velocity does not, may best be explained by sensory axon loss.
The histological analysis of tibial nerve cross sections revealed hypomyelinated axons next to axonal loss and increased abundance of connective tissue in CMT rats ( Fig. 1E ; see also Sereda et al., 1996) . These common features of CMT subtype 1A pathology were most prominent in severely affected CMT rats (Fig. 1E) . The absolute number of myelinated axons per tibial nerve, as a direct measure of disease severity, was significantly different between wild-type rats (2963 AE 33 axons; n = 4), mildly affected CMT rats (2811 AE 23 axons; n = 7) and severely affected CMT rats (2672 AE 19 axons; n = 10) (Fig. 1F) .
To reliably identify differentially affected CMT rats, two robust phenotype measures, grip strength and the absolute number of Phenotype analysis was then performed at the age of 3, 5, 7 and 9 weeks by measuring the grip strength of the fore-limbs. At 9 weeks of age, all rodents were sacrificed. Tibial nerve was assessed for histology and again, skin and sciatic nerve tissue were sampled for transcriptional analysis. After identification of severely and mildly affected CMT rats (n = 5 each), sciatic nerve (biologically relevant) and skin tissue (clinically relevant) samples were analysed by gene expression profiling to identify putative prognostic (Day 7) and disease severity myelinated axons per tibial nerve were combined and a CMT rat neuropathy score was generated (Table 1 and Supplementary  Fig. 1 ). Next, five CMT rats with the highest and the lowest CMT rat neuropathy score each were selected for comparative transcriptome analysis, and are henceforward referred to as mildly affected CMT rats (CMT rat neuropathy score 0-3) and severely affected CMT rats (CMT rat neuropathy score 9-10). All remaining rats were grouped as moderately affected animals (CMT rat neuropathy score 4-8).
RNA expression profiles in sciatic nerve codefine the clinical severity in Charcot-Marie-Tooth rats
Comparative microarray analysis was performed with messenger RNA samples derived from Day 7 and Day 63 sciatic nerve of mildly affected and severely affected CMT rats applying three biological replicates in each group. We identified dysregulated genes via the criteria magnitude of regulation (1.5-fold) and level of significance (P 5 0.05). In sciatic nerve, at Day 7, 74 genes were upregulated and five genes downregulated and at Day 63, 81 genes were upregulated and 132 genes downregulated in severely affected compared with mildly affected CMT rats (Table 2) . By annotation of dysregulated messenger RNAs using gene ontology, a pronounced involvement of metabolic processes with regard to disease severity was detected in sciatic nerve tissue ( Fig. 2A) . The proportion of metabolism related dysregulated genes was more prominent at Day 63 compared with Day 7. To further specify the dysregulated genes, we used a knowledgebased approach; the gene set enrichment analysis (Subramanian et al., 2005) . Importantly, we identified a strong dysregulation of genes involved in the metabolism of lipids (Fig. 2B ). Most lipid metabolism associated genes were downregulated in sciatic nerves of CMT rats when compared with wild-type animals in development (Day 7) as well as in young adulthood (Day 63) (Fig. 2B) . At Day 7, lipid metabolism associated genes showed an average upregulation in severely affected compared with mildly affected CMT rats, whereas an inverse regulation was observed at the age of 9 weeks (Day 63) (Fig. 2B) .
Validation of candidate genes via real time-polymerase chain reaction in sciatic nerve
For validation by real time-polymerase chain reaction at the single animal level (n = 5 per group), we selected the most prominent dysregulated candidate messenger RNAs of different gene sets (Table 3) . In particular, genes involved in fatty acid metabolism and cell growth were found to be predominantly dysregulated at both time points (11 genes at Day 63, six genes at Day 7). Grip strength analysis (fore-limbs) of wild-type (dotted line) in comparison with CMT rats (continuous line) at 3, 5, 7 and 9 weeks of age (mean, SD, *P 5 0.05, Student's t-test). Individual grip strength values are depicted on the right, defining mildly (n = 7) and severely (n = 10) affected CMT rats at 9 weeks of age (green and red dots, respectively). These animals were then chosen for electrophysiological (C and D), histological (E and F) and nociceptive hot plate analysis (G and H) and compared with wild-type controls (n = 10). (D) Quantification of compound muscle action potentials (CMAP) recorded after proximal stimulation show a significant decrease from wild-type rats to mildly and severely CMT rats. Representative traces for each group are depicted in (C) (m = stimulus, n = distal motor latency). (E) Representative light microscopic pictures of tibial nerve cross sections of wild-type rats and mildly-and severely affected CMT rats, aged 9 weeks. Arrows depict demyelinated axons, which are increased in severely, compared with mildly affected animals (scale bar = 10 mm). (F) Quantification of total myelinated axons per tibial nerve in 9-week-old rats. A significant decrease in axon number was observed when comparing wild-type rats to mildly and severely affected CMT rats. (G) Nociceptive hot plate analysis was performed by placing rats on a 55 C thermo plate and measuring latency to pain response as defined by hindpaw licking. (H) Latencies increased when comparing mildly to severely affected CMT rats, but not between comparing wild-type and mildly affected. Asterisks upon boxes indicate significant differences to age and sex matched wild-type control animals. (mean; SEM; *P 5 0.05, ***P 5 0.005). qRT-PCR = semi-quantitative real time-polymerase chain reaction. CMT rat neuropathy score 0-3: Mildly affected CMT rat neuropathy score 4-8:
Moderately affected CMT rat neuropathy score 9-10:
Severely affected Myelinated axons per tibial nerve and fore-limb grip strength define the CMT rat neuropathy score. For each parameter, six score classes were designed with respect to decrease in axon number and grip strength. The CMT rat neuropathy score was composed by adding both parameter scores (myelinated axons per tibial nerve and fore-limb grip strength) resulting in a maximum CMT rat neuropathy score of 10. Three disease severity classes were then specified: mildly affected, CMT rat neuropathy score 0-3; moderately affected, CMT rat neuropathy score 4-8; and severely affected, CMT rat neuropathy score 9-10. Table 2 ). Depicted are differentially expressed genes validated by semi-quantitative real time-polymerase chain reaction at the single animal level (n = 5) in both sciatic nerve and skin at Day 7 and Day 63. Validated genes were annotated to known functions. The ratio of mean expression values of severely and mildly affected CMT rats is indicated with P-value (ratio 41: upregulation in severely affected CMT rats). Upregulated genes in severely affected CMT rats are highlighted in red, whereas downregulated genes are highlighted in blue (dark: P 5 0.05; light: P 5 0.01, respectively). Adipoq = adiponectin; Car3 = carbonic anhydrase 3; Cldn1 = claudin 1; Ctsa = cathepsin A; Cxcl12 = chemokine ligand 12 C-X-C motif; Ddt = dopachrome D-tautomerase; Dpt = dermatopontin; Ebf1 = early B-cell factor 1; Fn3krp = rouctosamine 3 kinase related protein; Gdnf = glial cell line derived neurotrophic factor; Gstp2 = glutathione S-transferase, pi, type 2; Gstt2 = glutathione S-transferase, theta, type 2; Id3 = inhibitor of DNA binding 3; Igf1 = insulin-like growth factor 1; Igfbp5 = insulin-like growth factor binding protein 5; Il16 = interleukin 16; Il1r1 = interleukin 1 receptor 1; Myl1v2 = myosin light chain 1, variant 2; Nefl = neurofilament light chain; Nefm; neurofilament medium chain; Nexn = nexilin; Nnt = nicotinamide nucleotide transhydrogenase; Pde2a = phosphodiesterase 2b; Pde3b = phosphodiesterase 3b; Pmp22 = peripheral myelin protein 22 kDa; Prkar2b = protein kinase, cAMP-dependent, regulatory, type II, beta; Prx = periaxin; Rbp4 = retinol binding protein 4; Ribin = rRNA promoter binding protein; Scd1 = stearoyl Co-A-desaturase1; Sprr1al = small proline rich repeat protein 1a like; Ssg1 = steroid sensitive gene 1; Tgfb3 = transforming growth factor, beta 3; Thrsp = thyroid hormone responsive; Cdo1 = cysteine dioxygenase 1.
Next, we validated the three most strongly regulated genes of the lipid metabolism gene set (identified by gene set enrichment analysis; Fig. 2B ) via real time-polymerase chain reaction and extended our analysis to moderately affected CMT rats and wild-type animals (Fig. 2C) . In the Day 63 sciatic nerve, the messenger RNA expression ratios for the Pparg, lipoprotein lipase (Lpl) and thyroid hormone responsive protein (Thrsp) genes in sciatic nerve were decreased in severely affected compared with mildly affected CMT rats (fold changes: peroxisome proliferationactivated receptor gamma (Pparg) = 0.26, P 5 0.005; Lpl = 0.49, P 5 0.01; Thrsp = 0.23, P 5 0.001; Fig. 2C and Table 3 ). Conversely, in the Day 7 sciatic nerve, the relative messenger RNA expression levels of these genes were increased in CMT rats with severe disease progression compared with CMT rats with a mild disease progression (fold changes: Pparg = 3.17, P 5 0.01; Lpl = 2.20, P 5 0.05; Thrsp = 2.05, P 5 0.05; Fig. 2C and Table 3 ). In summary, messenger RNA levels of lipid metabolism associated genes correlated with disease variability in sciatic nerve of CMT rats displaying an inverted expression when comparing early and late disease stages.
Prognostic and disease severity markers validated in skin biopsies of Charcot-Marie-Tooth rats
In the skin of CMT rats, hypomyelinated fibres can be observed in subcutaneous nerve bundles, which share features with the pathology of the sciatic nerve (Fig. 3A) . Comparative gene expression profiling of mildly affected versus severely affected CMT rats (Day 63) using skin tissue derived messenger RNA was performed with two technical replicates of five pooled samples per group. This approach resulted in 203 upregulated and 142 downregulated genes with respect to the criteria fold change (1.5) and significance (P 5 0.05) ( Table 2 ). Gene ontology annotation of dysregulated genes identified messenger RNAs related to cellular processes, to development/growth and, like in sciatic nerve tissue, to metabolic processes ( Fig. 3B and Table 3 ). Microarray analysis of skin tissue biopsied at Day 7 was not performed due to the low amount of isolated RNA.
Validation of biomarker candidates via real time-polymerase chain reaction in skin biopsies of Charcot-Marie-Tooth rats
At Day 63, most transcripts validated via real time-polymerase chain reaction (14 genes, P 5 0.05; Table 3 ) showed an upregulation in the skin of severely affected when compared with mildly affected CMT rats. Six genes were also differentially regulated at Day 7 as shown by real time-polymerase chain reaction (P 5 0.05; Table 3 ).
We then selected several candidates for extended real time-polymerase chain reaction validation in skin including moderately affected CMT rats and wild-type controls (in addition to severely and mildly affected CMT rats). Among the validated transcripts, glutathione S-transferase theta 2 (Gstt2) and cathepsin A (Ctsa) were found to be co-regulated in skin at both time points when comparing severely and mildly affected CMT rats (Table 3) . The relative expression ratios of the selected cutaneous disease severity markers in severely affected versus mildly affected CMT rats at Day 7 were 1.44 (P 5 0.05) for Gstt2 and 1.48 (P 5 0.05) for Ctsa (Fig. 3C and Table 3 ). At Day 63, the correlation with disease severity was even stronger, with a 1.44-fold change (P 5 0.01) for Gstt2 and 2.23 (P 5 0.001) for Ctsa (Fig. 3C and Table 3 ). Importantly, Gstt2 messenger RNA was also validated as a surrogate marker for disease severity in skin tissue after a successful therapeutic approach in CMT rats, which we had performed previously (Supplementary Fig. 2 ; see also Meyer zu Hö rste et al., 2007) .
Pparg was validated as a marker for disease severity in skin at Day 63 (3.17-fold change, P 5 0.05; Fig. 3C ). However, Pparg was not identified as a prognostic marker in skin, but in sciatic nerve tissue (Table 3) . Finally, Pmp22 was validated as a prognostic marker in skin at Day 7 (1.82-fold change, P 5 0.05). Importantly, Pmp22 was not identified as a disease severity marker in cutaneous and sciatic nerve tissue at Day 63 (Table 3) .
Biomarker validation in skin biopsies from patients with Charcot-MarieTooth subtype 1A
In order to translate our findings from the CMT rat directly to affected patients, we clinically examined the disease severity of 46 patients with genetically confirmed CMT subtype 1A, applying the CMT neuropathy score in addition to secondary outcome measures (Shy et al., 2005a) (Table 4) . We analysed 19 male and 27 female patients with CMT subtype 1A, aged 44.6 AE 12.7 years (mean AE SD), and the average CMT neuropathy score was calculated to be 14.6 AE 5.8 points (mean AE SD) (Table 4 ). This average disease severity fits well with reports from other clinical studies (Shy et al., 2008; Pareyson et al., 2011) . We next sampled skin biopsies of this CMT subtype 1A cohort to validate putative disease severity markers. We chose five genes as the most promising candidates using the criteria fold change and co-regulation between different time points and tissues in the CMT rat (Table 3) .
Exploratory statistical linear regression modelling was used to identify surrogate disease severity markers and variables for the CMT neuropathy score (Fig. 4A) . The variables of the resulting models were used in addition to model the CMT neuropathy score subcategories of sensory symptoms (Fig. 4B ) and motor symptoms (Fig. 4C ) (for complete statistical report see Supplementary material).
Importantly, the marker GSTT2 messenger RNA significantly influenced all three CMT neuropathy score-related models. The P-values for GSTT2 messenger RNA were found to be P = 0.0006 for the CMT neuropathy score, P = 0.0002 for sensory symptoms and P = 0.0126 for motor symptoms. The marker CTSA messenger RNA showed a considerable statistical influence in the CMT neuropathy score-related models, but not to the same degree and with the same consistency as GSTT2 (CMT neuropathy score, P = 0.0065; sensory symptoms, P = 0.0313; motor symptoms, P = 0.0114). As expected, age significantly correlated with the disease variability and was therefore also included in CMT neuropathy score-related surrogate marker models (CMT neuropathy score, P = 0.0042; sensory symptoms, P = 0.0713; motor symptoms, P = 0.0032). In multiple linear regression models, potentially predictive markers/parameters for CMT neuropathy score should have an adjusted P-value (see Supplementary material), which has to be below the standard alpha level of 0.05 (Table 4) . Importantly, this holds true in the CMT neuropathy score model for the marker GSTT2 with an adjusted P-value of Figure 3 Cutaneous messenger RNA disease severity markers in CMT rats. (A) Light microscopic (scale bar = 50 mm) image of methylene blue stained cross section of rat skin. Three dermal layers can be discriminated: epidermis (ED), dermis (D) and subcutis (SC). Subcutaneous nerve fibre bundles can be found and hypomyelination of axons in dermal nerve fibres of CMT rat is evident compared with wild-type (WT) control animal (indicated by arrows, scale bar = 10 mm). (B) Pie chart of dysregulated genes in skin between mildly (MA) and severely (SA) affected CMT rats with annotation to gene ontology classes at Day 63. (C) Validation of selected candidate messenger RNAs Gstt2, Ctsa, Pmp22 and Pparg was performed by semi-quantitative real time-polymerase chain reaction. Expression of wild-type rats, mildly affected (MA, CMT rat neuropathy score 0-3), moderately affected (MoA, with a CMT rat neuropathy score, CMT rat neuropathy score of 4-8) and severely affected CMT rats (SA, CMT rat neuropathy score 9-10) are shown (n = 5 each). At Day 63 (right), severely affected CMT rats show upregulation of Gstt2, Ctsa and Pparg messenger RNA levels compared with mildly affected CMT rats. However, at Day 7 (left), messenger RNA levels of Gstt2, Ctsa and Pmp22 are upregulated in skin tissue of CMT rats, which display a severe disease phenotype at Day 63 (SA, CMT rat neuropathy score 9-10). Asterisks upon bar indicates significant difference to wild-type expression level (mean, SEM, t-test *P 5 0.05, **P 5 0.01, ***P 5 0.005). RFU = relative fluorescent units.
P adj = 0.0072. Also, age was found to be significant after correction of the P-value (P adj = 0.0465). In contrast, the marker CTSA displayed only borderline significance when the adjusted P-value is used (P adj = 0.0649). As indicated in the statistical report (Supplementary material), adjusted P-values were not calculated for the subcategories of sensory and motor symptoms as no model optimization based on stepwise linear regression was performed for these target variables. The P-values show that the model selected for CMT neuropathy score fits well for both subcategories. The 'age' variable had a stronger influence on motor symptoms while GSTT2 had a stronger correlation with sensory symptoms. The estimated regression coefficients ('Estimate' in Table 5 ) indicate the size of the predicted change of the dependent target variable if the corresponding independent variable changes by one unit while the other independent variables in the model are kept constant (e.g. the CMT neuropathy score changes 0.159 points if the age is changed by 1 year).
Taken together, by combination of cutaneous expression of GSTT2 and CTSA messenger RNA and age, the model predicts the CMT neuropathy score with an R 2 -value of 0.47, indicating that $47% of total variance of the CMT neuropathy score-related disease severity can be explained by this model (Fig. 4A ). The R 2 values for models of motor symptoms and sensory symptoms are both 0.41 ( Fig. 4B and C) . The expression of a further candidate gene, PPARG, shows a significant correlation only with a secondary clinical outcome measure, the 10-m Walking Test (P = 0.0019, Fig. 4D ). The tested CMT rat disease marker insulin-like growth factor binding protein 5 (IGFBP5) and carbonic anhydrase 3 (CA3) messenger RNAs revealed no influential values to the CMT neuropathy score-related models. All validated biomarkers in CMT rats and patients with CMT subtype 1A are summarized in Table 6 .
Discussion
The factors that determine the interindividual clinical variability and the course of disease in patients with CMT subtype 1A are poorly understood. In the present study, we utilized the disease variability of the CMT rat model to identify messenger RNA transcripts from sciatic nerve and skin biopsies that may serve as biomarkers of disease severity. More specifically, we identified prognostic markers, genes whose expression levels at young age (Day 7) predict clinical impairments at later age (Day 63). We also identified surrogate markers of disease severity at the age of 9 weeks (Day 63). Gene products involved in lipid metabolism were most obviously differentially regulated in sciatic nerve. Importantly, in a direct translational approach, we were able to validate cutaneous disease severity biomarker transcripts in patients with CMT subtype 1A.
Expression of biomarkers in sciatic nerve of Charcot-Marie-Tooth rats
Genes related to lipid metabolism were predominantly downregulated in sciatic nerve tissue of CMT rats when compared with controls at Day 7 as well as at the age of 9 weeks (Day 63) (Fig. 2B ). These findings are in accordance with previous observations (Giambonini-Brugnoli et al., 2005; Vigo et al., 2005) and can be regarded as secondary transcriptional response of Schwann cells to the demyelinating pathology. That severely affected CMT rats show a more pronounced downregulation of these genes compared with mildly affected CMT rats at Day 63 (Table 3 ) may thus also reflect the increased amount of demyelination and axonal loss ( Fig. 1E and F ; Sereda et al., 2003) . We chose to examine transcriptional expression at the time point Day 7, as there was no phenotype visible and the number of myelinated axons was unaltered in CMT rats when compared with wild-type controls (data not shown). This was thought to relate to time points in young patients with CMT subtype 1A who have not yet developed a clinical phenotype, but who had received a positive genetic analysis. In contrast to Day 63, the validated prognostic marker transcripts of lipid metabolism were upregulated in sciatic nerve tissue in CMT rats, which developed a severe phenotype at later disease stages ( Fig. 2B and C; Table 3 ). Why are the expression levels inversely regulated at early versus late time points? In this regard, we note that 2 days earlier in development (at Day 5) the majority of myelinated axons in sciatic nerve from CMT rats were hypermyelinated ( Supplementary Fig.  3 ), indicating that CMT subtype 1A is a dysmyelinating disease, a notion that is being discussed in spite of the early slowing of nerve conduction velocity in young patients with CMT subtype 1A (Yiu et al., 2008) . Hence, increased myelin synthesis may have caused upregulation of lipid genes in CMT rats with severe disease progression at Day 7. We cannot, however, state that the degree of hypermyelination (i.e. increased myelin wraps per axon leading In the cohort of 46 probands with an average age of 44 years (mean = 44.6; SD = 12.7) we performed the CMT neuropathy score and secondary outcome measures of disease severity in genetically confirmed patients with CMT subtype 1A. We performed neurophysiological examination of the compound muscle action potential and sensory nerve action potential as part of the CMT neuropathy score and 10-m Walking Test, Nine-peg-hole Test, Visual Analogue Score (VAS) as well as the dynamometry of single muscles or muscle groups. In our cohort, the mean time of the 10-m Walking Test was 6.1 s (SD = 3.3) and the Nine-peg-hole Test took 27.3 s (SD = 18.9) on average. We measured an average pinch grip of 31.2 N (SD = 24.8) and a mean of the foot dorsiflexion of 19.7 N (SD = 21.9).
Figure 4
Marker validation in patients with CMT subtype 1A. We examined the clinical variability of 46 genetically determined patients with CMT subtype 1A ( + = female, n = 27; o = male, n = 19) by applying the CMT neuropathy score (CMTNS) and performed a skin biopsy for subsequent real time-polymerase chain reaction analysis for validation of putative disease markers. Exploratory statistical linear regression modelling was used to identify predictive markers and variables for CMT neuropathy score. (A) The variables of the resulting models (GSTT2 messenger RNA, CTSA messenger RNA and age) were used in addition to model the CMT neuropathy score subcategories of sensory symptoms (B) and motor symptoms (C). The individual contribution of single marker parameters are plotted in leverage graphs next to the CMT neuropathy score-related models. Additionally, cutaneous PPARG messenger RNA expression shows significant correlation with the 10-m Walking Test (D).
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Brain 2012: 135; 72-87 | 83 to a lower g-ratio) at Day 7 directly predisposes to increased axonal loss at later time points. Nevertheless, it is tempting to speculate that early dysregulation of lipid metabolism associated genes triggered by Pmp22 overexpression may cause more severe axonal loss and a clinical phenotype in CMT subtype 1A as lipids constitute $70% of total myelin and lipid metabolism plays an important role in myelination and demyelination (Garbay et al., 2000; Saher et al., 2009) . Further focus on the role of PMP22 with regard to lipid metabolism in the CMT subtype 1A disease pathology will elucidate this question. Interestingly, sciatic nerve Pmp22 messenger RNA expression itself did not contribute to disease severity at Day 7 and Day 63 (Table 3) . Pparg, Lpl and Thrsp messenger RNAs are examples of lipid metabolism-related, differentially regulated genes at both time points, Day 7 and Day 63, in the sciatic nerve of CMT rats (Fig. 2D) . These genes may therefore indicate disease progression modifiers. Pparg messenger RNA was also identified as a disease severity marker in skin of CMT rats at Day 63 (Fig. 3C ). In patients with CMT subtype 1A, the cutaneous expression of PPARG shows significant correlation with the 10-m Walking Test, a secondary motor outcome measure (Fig. 4D) , which makes it a particularly interesting gene with regard to CMT subtype 1A pathology.
PPARG protein is a lipid-activated member of the nuclear receptor superfamily of transcription factors and controls the expression of a battery of genes involved in lipid metabolism (reviewed in Tontonoz and Spiegelmann, 2008) . With regard to the PNS, two reports indicate that PPARG ligands can reduce neuropathic pain in animal models of sciatic nerve injury (Seltzer et al., 1990; Maeda et al., 2008) . After spinal cord injury, application of PPARG agonists can prevent motor dysfunction and myelin loss in the CNS of adult rats (Park et al., 2007) . Treatment with agonistic PPARG ligands may therefore constitute a future therapeutic rational in CMT subtype 1A.
Expression of biomarkers in skin biopsies of Charcot-Marie-Tooth rats Nerve biopsies constitute an important, but invasive diagnostic tool. In the more easily accessible cutaneous tissue of patients with CMT subtype 1A and different animal models of hereditary neuropathies, pathologically demyelinated axons as well as altered myelin gene expression in subcutaneous nerve bundles could be identified ( Fig. 3A; Potentially predictive markers/parameters for CMT neuropathy score should have an adjusted P-value (right) below the standard alpha level of 0.05. This is true in the CMT neuropathy score model for the marker GSTT2 and for age; the marker CTSA is only borderline significant if the adjusted P-value is used. No adjusted P-values were calculated for the subcategories of sensory and motor symptoms as no model optimization based on stepwise linear regression had been done for these target variables. The estimated regression coefficients ('Estimate' column) indicate the size of the predicted change of the target variable if the corresponding independent variable changes by one unit while the other independent variables in the model are kept constant. The fourth column gives the standard error of the estimate. The t-value in the fifth column is the ratio of Estimate and its standard error. The well known P-value can be calculated from the t-value and the number of degrees of freedom. n.a. = not analysed. 
Validation of selected prognostic (Day 7) and disease severity markers (Day 63) in the CMT rat and in patients with CMT subtype 1A. Arrows indicate up-or downregulation in severely affected CMT rats and patients with CMT subtype 1A. Minus sign indicates no regulation, whereas n.a. denotes not analysed. Dacci et al., 2010) . With regard to the powerful translational aspect of skin biopsies in patients (Lauria et al., 2011) we therefore determined whether biomarkers could be identified from skin biopsies in CMT rats. In general, the expression of candidate biomarker transcripts highly differed between sciatic nerve and skin (Tables 3 and 6 ). Which cells contribute to the expression of genes in skin? Despite the presence of myelinated nerve fibres in the subcutaneous layer of skin tissue (Fig. 3A) , a predominant contribution of Schwann cell-derived messenger RNA to the entire dermal transcriptome is very unlikely given the vast majority of dermal cells such as fibroblasts and keratinocytes (Kanitakis, 2002) .
The altered gene expression observed in skin biopsies may reflect loss of axons and sensory effector organs in skin tissue (Saporta et al., 2009) . Alternatively, skin derived fibroblasts and keratinocytes may be subjected to secondary remodelling processes of subcutaneous and cutaneous tissue as a consequence of the atrophy of the small finger muscles, a described early and sensitive feature of patients with CMT subtype 1A (Berciano et al., 2000) . Thus, the altered gene expression profile from cutaneous tissue may be seen as a sensitive surrogate marker of axonal loss and consecutive muscle atrophy.
In our transcriptional analysis of dermal tissue we validated six genes at Day 7, which constitute prognostic markers from skin biopsies in the CMT rat model (Table 3) . Importantly, Pmp22 was the most robust identified cutaneous prognostic marker, since CMT rats with moderate disease progression already showed a significant upregulation when compared with wild-type controls at Day 7 (Fig. 3C) .
Ctsa and Gstt2 were identified as prognostic and disease severity markers in skin of the CMT rat. Moreover, we demonstrate that the dermal messenger RNA expression of Gstt2 also correlates with the phenotype of CMT rats after an experimental therapeutic approach with a progesterone antagonist, which we had performed in an earlier study (Supplementary Fig. 2 ; Meyer zu Hö rste et al., 2007) , indicating that Gstt2 may be a promising cutaneous disease severity marker for monitoring future therapeutic trials in patients ( Supplementary Fig. 2 ).
Validation of biomarkers in skin biopsies of patients with Charcot-Marie-Tooth subtype 1A
In a cohort of 46 patients with CMT subtype 1A, we show significant correlations between the CMT neuropathy score and its subcategories (sensory and motor symptoms), with the dermal messenger RNA expressions of GSTT2 and CTSA (Fig. 4A-C) . We could also confirm previous findings (Shy et al., 2008) , that the age of patients with CMT subtype 1A correlates with disease severity. Importantly, by combination of the variables GSTT2 and CTSA messenger RNA and age, the surrogate marker value for the CMT neuropathy score shows an R 2 of 0.47 (47%) (Fig. 4A ). The R 2 values for the models 'motor symptoms' and 'sensory symptoms' are both 0.41 (41%) (Fig. 4B and C) . The effect sizes of 47% and 41% can be interpreted as 'moderate to strong' under classical statistical criteria (Cohen, 1988; Evans, 1996) .
The major limitations of these results are that the models in the statistical analysis are data derived and not preplanned. The development of applicable biomarkers necessitates extensive evaluation in larger studies with explicit, criterion-based, quantitative and multidimensional hierarchical levels of evidence schema (Lassere, 2008; Pletcher and Pignone, 2011) . However, the statistical models with formally significant predictors in our study can be considered as appropriate to generate promising hypotheses (Supplementary material). Our data demonstrate that-in principle-disease severity can be correlated with cutaneous messenger RNA expression in the CMT rat and in patients affected with CMT subtype 1A. Currently, we are performing a larger confirmative study to challenge all identified rodent biomarkers in patients with CMT subtype 1A on newly captured data. We aim to provide clinicians with applicable biomarkers which may find implementation in future therapy trials.
The statistical analysis of the present human data was performed regardless of potentially perturbing influential factors such as sex, medications, comorbidities and other risk factors. Although environmental factors can be assumed to influence CMT disease severity, we observed a marked interindividual variability in disease severity in CMT rats that were kept on an outbred background under identical conditions. Therefore, in CMT rats, we speculate that environmental factors can be largely excluded to have caused disease variability, indicating that intrinsic genetic factors suffice to entail differential disease progression.
Importantly, three of five tested CMT rat-derived cutaneous disease severity markers showed an influence on the CMT neuropathy score-related models of patients with CMT subtype 1A. We conclude that the transcriptional regulation in skin tissue with regard to disease severity is similar when comparing CMT rats and patients with CMT subtype 1A. Finally, the approach in this study may reflect a practical approach to identify modifying genes, rather than using genome-wide searching (Genin et al., 2008) .
